Skip to main content

Table 1 Patient data

From: Proteomics analysis identifies new markers associated with capillary cerebral amyloid angiopathy in Alzheimer’s disease

MS/Validation Case Diagnosis M/F Age (years) Abeta Tau CERAD PMD APOE
MS 1 CAA type-1 F 75 A3 B3 C0c 6:00 44
MS 2 CAA type-1 F 96 A3 B3 C0c 4:20 43
MS 3 CAA type-1 M 68 A3a B1 C0c 6:05 44
MS 4 CAA type-1 F 78 A3 NA C0c 4:20 44
MS 5 CAA type-1 M 81 A3 B3 C2 6:30 44
MS 6 CAA type-1 F 95 A3 B3 C2 4:35 44
MS 7 CAA type-1 M 80 A3 B3 C0c 5:05 44
MS 8 AD F 82 A3 B3 C3 6:00 42
MS 9 AD F 72 A3 B3 C3 6:30 44
MS 10 AD F 81 A3 B3 C3 6:00 33
MS 11 AD F 73 A3 B3 C3 5:55 44
MS 12 AD M 84 A3 B3 C3 8:05 NA
MS 13 AD F 87 A3 B3 C3 5:45 43
MS 14 AD F 72 A3 B3 C3 5:55 23
MS 15 Control M 74 A0 B0 C0 8:05 33
MS 16 Control F 80 A1 B1 C0 6:58 43
MS 17 Control M 82 A0 B1 C0 5:10 23
MS 18 Control M 78 A0 B1 C0 17:40 33
MS 19 Control F 79 A0 B1 C0 18:13 33
MS 20 Control F 81 A0 B1 C0 4:25 33
V 21 CAA type-1 F 94 A3 B3 C3 04:30 43
V 22 CAA type-1 M 74 A3 B3 C3 03:25 NA
V 23 CAA type-1 F 87 A3 B3 C3 08:00 44
V 24 CAA type-1 F 84 A3 B3 C2 04:45 NA
V 25 CAA type-1 M 88 A3 B3 C3 03:55 NA
V 26 CAA type-1 M 75 A3 B3 C0 03:15 NA
V 27 AD M 64 A3 B3 C3 07:30 33
V 28 AD F 81 A3 B3 C3 05:15 43
V 29 AD F 90 A3 B3 C3 04:45 33
V 30 AD M 65 A3 B3 C3 06:00 43
V 31 AD F 73 A3 B3 C3 NA NA
V 32 AD F 90 A3 B3 C3 03:55 32
V 33 AD M 88 A3 B3 C3 04:40 43
V 34 AD M 74 A3 B3 C3 05:10 NA
V 35 Control M 73 A0 B0 C0 24:45 33
V 36 Control M 71 A0 B1 C0 07:40 33
V 37 Control F 82 A0 B1 C0 07:00 33
V 38 Control M 56 A0 B0 C0 09:15 43
V 39 Control M 62 A0 B1 C0 07:20 33
V 40 Control M 76 A0 B0 C0 06:45 33
V 41 Control M 93 A0 B1 C0 05:05 33
V 42 Control F 60 A0 B0 C0 08:10 32
V 43 Cotton wool M 72 A3 B3 C0c 05:15 43
V 44 Prp-CAA F 57 A0 B0b C0 24:00 NA
V 45 CADASIL M 73 A0 B0 C0 31:45 NA
V 46 CARASAL F 55 A1 B1 C0 04:00 NA
V 47 Hyper tension related SVD F 92 A1 B2 C0 07:25 NA
  1. Alzheimer’s disease: AD, cerebral amyloid angiopathy: CAA, M: male, F: female, post mortem delay: PMD, not available/not applicable: NA, used for mass spectrometry analysis: MS, used for validation: V. (aAβ only present as dysphoric CAA) (bFocal tau accumulation around blood vessels with prp-amyloid deposits) (conly dyshoric angiopathy in gallyas staining)